Bethaherpesviruses in Children Who Are Immune Suppressed - NCT00641121-44195 (Clinical Trial 210601)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy210601.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Cleveland |
|
State:
|
|
OH |
| Zip Code: |
|
44195 |
| Conditions: |
|
Immune Suppressed Children |
| Purpose: |
|
Unexplained fever in children with cancer is a common occurrence, often requiring hospital
admission for evaluation and treatment with intravenous antibiotics. While empiric use of
intravenous antibiotics is the norm in this population, between 48-70% of febrile and
neutropenic episodes remain without an identifiable source. An understudied area is the
potential role of betaherpesvirus infections in such febrile episodes. These viruses are
significant pathogens in patients who become immunocompromised in conjunction with organ
transplantation or acquired immune deficiency syndrome (AIDS). It is possible that they are
similarly pathogenic in children who become immunocompromised due to cancer chemotherapy.
Thus, we will investigate the association between the betaherpesviruses and fever in
children with cancer. The betaherpesviruses include cytomegalovirus (CMV), human herpesvirus
6A (HHV-6A), human herpesvirus 6B (HHV-6B), and human herpesvirus 7 (HHV-7). These viruses
are grouped based on shared biological and genetic properties. Each is commonly acquired in
childhood, persists in the human host, and can reactivate. Reactivation occurs
intermittently throughout life in healthy individuals and is seldom associated with disease.
Immune suppression is associated with a higher likelihood of reactivation and clinical
disease. Latency of these viruses involves highly regulated processes that result in the
viruses evading destruction and persisting within the host. Should balance be disrupted, as
with cancer and anticancer therapy altering the normal host state, the environment may
become favorable for betaherpesvirus reactivation, leading to disease and further
alterations of the immune system.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Newly diagnosed with cancer (leukemia, lymphoma, or solid tumor)
2. Undergoing solid organ pre-transplantation evaluation
3. Age birth to 21 years
Exclusion Criteria:
1. Unwilling to participate in the study
2. Unwilling to have specimens stored for future research
3. Clinical conditions preclude the required amount of blood to be drawn for the study
4. Patient has malignancy that has relapsed
5. Patient is not a primary transplant candidate (ie. has already had a solid organ
transplant) - |
|
|
|
| Study is available at: |
|
Cleveland Clinic
Cleveland, OH 44195
United States
Primary Contact:
Donna Londrico, RN
Phone: 216-444-9620
Secondary Contact:
Johanna Goldfarb, MD
Phone: 216-444-2200 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|